Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID-19 prevention.
Julia TreplChloé PasinDominik SchneidawindNicolas J MuellerMarkus G ManzAndriyana K BankovaIrene A AbelaPublished in: British journal of haematology (2024)
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients exhibit an increased risk of COVID-19, particularly in the early post-transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS-CoV-2 infection in allo-HCT recipients who received tixagevimab/cilgavimab pre-exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS-CoV-2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS-CoV-2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- men who have sex with men
- cell therapy
- single cell
- monoclonal antibody
- stem cell transplantation
- bone marrow
- kidney transplantation
- case report
- stem cells
- hematopoietic stem cell
- high dose
- risk assessment
- high resolution
- cell cycle arrest
- cell death
- replacement therapy
- atomic force microscopy
- pi k akt
- mass spectrometry